Online inquiry

IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11660MR)

This product GTTS-WQ11660MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza B infection research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11660MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ658MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 8c10
GTTS-WQ12099MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ7577MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA G-CSF
GTTS-WQ12801MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ6851MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ666MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 8H9
GTTS-WQ10342MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ941MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-321
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW